Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P59510
UPID:
ATS20_HUMAN
Alternative names:
-
Alternative UPACC:
P59510; A6NNC9; J3QT00
Background:
A disintegrin and metalloproteinase with thrombospondin motifs 20 (ADAMTS20) is implicated in the tissue-remodeling process, crucial in both normal and pathological conditions. Its unique GON domain suggests a protease-independent role in facilitating the transport of secretory cargos from the endoplasmic reticulum to the Golgi apparatus.
Therapeutic significance:
Understanding the role of A disintegrin and metalloproteinase with thrombospondin motifs 20 could open doors to potential therapeutic strategies, especially in diseases where tissue remodeling plays a critical role.